Compare CRNT & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNT | ATYR |
|---|---|---|
| Founded | 1996 | 2005 |
| Country | Israel | United States |
| Employees | N/A | 59 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.7M | 83.3M |
| IPO Year | 2000 | N/A |
| Metric | CRNT | ATYR |
|---|---|---|
| Price | $2.32 | $0.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 8 |
| Target Price | $4.00 | ★ $4.20 |
| AVG Volume (30 Days) | 365.7K | ★ 1.3M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.32 | $9,628.95 |
| Revenue Next Year | $6.43 | $156.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $0.64 |
| 52 Week High | $2.84 | $7.29 |
| Indicator | CRNT | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 47.38 |
| Support Level | $2.23 | $0.67 |
| Resistance Level | $2.40 | $1.09 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 80.65 | 28.05 |
Ceragon Networks Ltd is a wireless transport company in terms of unit shipments and wide distribution of its business, providing high-capacity wireless connectivity solutions to markets across various industries, mainly wireless (mobile) networks service providers. Geographically the company generates the key revenue from India. The company also has presence in North America, Europe, Africa, Asia-Pacific and Middle East, and Latin America. The company's products include IP-50 Platform, IP-20 Platform, Pointlink.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).